Novartis v. MSN Pharmaceuticals: Federal Circuit Affirms Entresto® Patent Portfolio
Novartis AG secured a Federal Circuit affirmance of its nine-patent Entresto® (sacubitril/valsartan) portfolio against MSN Pharmaceuticals and three related entities in Case 24-2211. The appellate court found no reversible error in the district court’s infringement ruling, reinforcing protection across three dosage strengths of the blockbuster heart-failure drug. The proceeding resolved in just 113 days.
Federal Circuit seals Novartis’s Entresto® fortress against generic entry
In Case 24-2211, Novartis AG appealed — or successfully defended — an infringement action before the United States Court of Appeals for the Federal Circuit, filed on 13 August 2024 and resolved on 4 December 2024. The dispute centred on nine US patents covering Entresto® (sacubitril/valsartan) tablets at dosage strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, a fixed-dose combination therapy approved for heart failure with reduced ejection fraction. The defendants comprised MSN Pharmaceuticals Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and Gerbera Therapeutics Inc. — collectively representing the generic development and commercialisation supply chain for the challenged formulation.
The Federal Circuit issued a one-line affirmance — ‘AFFIRMED’ — indicating the appellate panel found no reversible legal or factual error in the underlying infringement ruling. For Novartis, the affirmance means the nine-patent estate protecting Entresto® remains judicially validated and enforceable. For the MSN entities and Gerbera Therapeutics, the ruling forecloses this particular appellate avenue, leaving the ANDA pathway effectively blocked absent a successful inter partes review or further en banc or Supreme Court petition.
The 113-day duration from filing to affirmance is notably compressed relative to typical Federal Circuit patent timelines, suggesting this may have proceeded on a summary or expedited basis — or that the panel found the district court record sufficiently clear to dispose of the appeal without extended briefing. The public record does not disclose whether a Rule 36 judgment or full opinion accompanied the affirmance, which matters because a Rule 36 summary affirmance carries no precedential weight. What drove the speed and the precise legal grounds affirmed remain, to some extent, opaque from docket data alone.
Filing to Appeal Dismissed in 113 days
113 days — faster than the Federal Circuit’s median patent appeal duration of ~18 months
Federal Circuit affirms: what the Entresto® ruling means for both parties
Affirmance means the lower court’s ruling stands in full
When the Federal Circuit issues an ‘AFFIRMED’ disposition, it confirms that the court below committed no reversible error — whether in claim construction, infringement findings, or validity analysis. The appellate court does not conduct a new trial; it reviews legal questions de novo and factual findings for clear error. An affirmance here means the district court’s infringement determination across all nine asserted Entresto® patents was upheld as legally sound.
No reversible error foundNovartis’s nine-patent Entresto® estate is judicially reinforced
The affirmance materially strengthens Novartis’s enforcement posture. All nine patents — spanning composition, formulation, and method-of-use claims for sacubitril/valsartan — have survived this appellate challenge intact. Courts and future ANDA litigants must now contend with a Federal Circuit-validated claim construction and infringement record. The ruling also raises the litigation risk calculus for any other generics holding Paragraph IV certifications against Entresto®.
Patent enforceability strengthenedMSN’s appellate options are exhausted at the Federal Circuit level
For MSN Pharmaceuticals and its co-defendants, the affirmance closes the direct appellate route. Remaining procedural options are narrow: a petition for rehearing en banc (rarely granted), a petition for certiorari to the Supreme Court, or a collateral attack via inter partes review at the USPTO. Each path carries significant cost and low probability of success given a clean Federal Circuit affirmance. Commercial launch of the generic sacubitril/valsartan product is effectively enjoined unless patent expiry or a separate IPR outcome changes the landscape.
Generic launch pathway blockedEntresto® exclusivity window firms up; sector risk repricing expected
Entresto® is among Novartis’s highest-revenue cardiovascular assets. A Federal Circuit affirmance across nine patents signals that the exclusivity runway is judicially secured beyond this challenge. For the broader cardiovascular generics sector, the ruling raises the evidentiary bar for Paragraph IV certification strategies against multi-patent ANDA estates. Competitors and investors will likely recalibrate generic entry timelines and royalty expectations for sacubitril/valsartan accordingly.
Generic entry timeline resetFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Novartis AG — global pharmaceutical company; holder of US8101659B2 and 8 related Entresto® patentsSearch in Eureka ↗ |
| Defendant | Msn Pharmaceuticals, Inc. | Company | MSN Pharmaceuticals Inc. and affiliates — generic drug developers seeking ANDA approval for sacubitril/valsartanSearch in Eureka ↗ |
| Co-Defendant | GERBERA THERAPEUTICS INC. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Life Sciences Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Christopher Earl Loh | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Deanne Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared Levi Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Joel F. Wacks | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Rebecca Emily Weires | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Seth W. Lloyd | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Kevin E. Warner Esq. | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard Charles Weinblatt | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Richard Juang | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Ronald M. Daignault | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | William A. Rakoczy | Attorney | Counsel for Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Daignault Iyer LLP | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Rakoczy, Molino, Mazzochi, Siwik LLP | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Msn Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s disposition — ‘THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED’ — is a complete appellate affirmance of the infringement finding below. The court applied de novo review to legal questions such as claim construction and clear-error review to factual findings. The terse phrasing is consistent with either a Rule 36 summary judgment (no precedential opinion) or a brief merits opinion; the public docket record does not distinguish these. For Novartis, the ruling is dispositive. For MSN, it forecloses direct appellate relief and substantially narrows the viable paths to market.
US8101659B2 and 8 further patents — Entresto® sacubitril/valsartan combination therapy
The nine patents in suit — anchored by US8101659B2 (application US12/147570) and extending through US11135192B2, US9937143B2, US9388134B2, US8796331B2, US11058667B2, US11096918B2, US9517226B2, and US8877938B2 — collectively protect Novartis’s Entresto® (sacubitril/valsartan) franchise. The patents span compound and salt form claims, formulation and dosage claims, and method-of-treatment claims for the dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) indicated for heart failure with reduced ejection fraction. The application dates range from the mid-2000s through the mid-2010s, reflecting a deliberate portfolio-building strategy across successive innovation layers.
The breadth of the asserted portfolio — nine patents across distinct claim categories for a single drug product — exemplifies Novartis’s layered IP strategy for Entresto®, which generates multi-billion-dollar annual revenues. Each patent creates an independent infringement exposure for any generic developer, meaning a successful challenge requires invalidating or designing around claims simultaneously in chemistry, formulation, and use. For cardiovascular drug developers, biosimilar strategists, and generic pharmaceutical companies, this estate represents one of the most densely protected small-molecule assets in the current ANDA litigation landscape.
Should you run an FTO against Entresto®’s nine-patent estate?
Any company developing a sacubitril/valsartan fixed-dose combination tablet — whether via ANDA, 505(b)(2), or a novel ARNi formulation — faces direct exposure to this Federal Circuit-affirmed nine-patent estate. The affirmance means that claim constructions and infringement findings are judicially settled at the appellate level for MSN’s specific product, but related products or formulation variations could still trigger independent infringement analysis. R&D teams and regulatory affairs professionals should treat each patent layer — compound, salt, formulation, and method — as a distinct FTO gate.
PatSnap Eureka’s FTO Search Agent enables IP teams to map all nine Entresto® patents simultaneously against a candidate compound or formulation, identify expiry dates by dosage-specific claim family, flag active IPR petitions that may affect enforceability, and surface design-around precedents from the prosecution history. For a portfolio this dense, automated claim-mapping across the full patent family — rather than sequential manual review — dramatically reduces the risk of missing an infringement vector before IND or ANDA filing.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ANDA patent appeals in cardiovascular pharmaceuticals
Explore Federal Circuit infringement appeals involving ANDA challenges to cardiovascular and heart-failure drug patents, including comparable multi-patent affirmance rulings.
What this case signals for the cardiovascular pharmaceutical IP landscape
A nine-patent affirmance at the Federal Circuit sets a durable precedent for how Entresto® exclusivity will be defended — and how generics must respond.
Multi-patent ANDA estates are significantly harder to dislodge on appeal
Novartis’s strategy of layering nine patents across composition, formulation, and use claims for a single product meant MSN had to overturn findings on multiple independent claim types simultaneously. Federal Circuit affirmance of the entire estate — not just one patent — signals that patent stacking in pharmaceutical portfolios delivers meaningful appellate durability.
Generic developers should front-load IPR challenges before district court trial
Post-affirmance, inter partes review at the USPTO represents MSN’s most viable remaining path. This case reinforces the broader strategic lesson: IPR petitions filed concurrently with or prior to ANDA litigation, rather than as a fallback, give generics the best chance to invalidate claims before a district court infringement record becomes entrenched and affirmed.
Novartis v Msn — key questions answered
The Federal Circuit affirmed the lower court’s infringement ruling in full across all nine Entresto® (sacubitril/valsartan) patents asserted against MSN Pharmaceuticals and co-defendants. The court found no reversible error, meaning the district court’s infringement findings stand and MSN’s path to generic market entry via this ANDA route is blocked.
Novartis asserted nine US patents: US8101659B2, US11135192B2, US9937143B2, US9388134B2, US8796331B2, US11058667B2, US11096918B2, US9517226B2, and US8877938B2. These collectively cover compound, salt, formulation, and method-of-treatment aspects of sacubitril/valsartan tablets at 24/26 mg, 49/51 mg, and 97/103 mg dosage strengths.
A Federal Circuit affirmance of an ANDA infringement ruling means the generic applicant cannot commercially launch until patent expiry or a successful post-grant challenge (e.g., IPR). For MSN, direct appellate options are exhausted short of en banc rehearing or Supreme Court certiorari, both of which are rarely granted. IPR petitions at the USPTO remain the most viable alternative path.
The public record does not explicitly explain Gerbera Therapeutics’ role, but its inclusion alongside the MSN manufacturing and pharmaceutical entities suggests it may be involved in the development, licensing, or commercialisation pathway for the challenged sacubitril/valsartan product — possibly implicating a 505(b)(2) or similar regulatory strategy. This is consistent with typical multi-entity ANDA litigation structures.
Case 24-2211 resolved in 113 days from filing (13 August 2024) to the affirmance order (4 December 2024). This is notably faster than the Federal Circuit’s typical patent appeal timeline of 12–18 months, suggesting the panel may have issued a Rule 36 summary affirmance or resolved the matter on expedited briefing. The compressed timeline limits the precedential value of the ruling but does not diminish its binding effect between the parties.
PatSnap Eureka searches patents and litigation data to answer instantly.